Full Spectrum Laboratories Secures U.S. Cannabinoid Biosynthesis Patent
News Jan 09, 2017 | Original Story From Teewinot Life Sciences Corporation
Teewinot Life Sciences Corporation (Teewinot), a global leader in the use of biosynthetic processes for the production of kilogram quantities of pharmaceutical grade cannabinoids, announced today that its Irish subsidiary, Full Spectrum Laboratories, Ltd. (FSL), was granted a U.S. patent entitled Chemical Engineering Processes and Apparatus for the Synthesis of Compounds. U.S. Patent No. 9,526,715 ("the '715 patent") was granted on December 27, 2016. The '715 patent claims are directed to biosynthetic processes for making cannabinoids.
Teewinot's CEO Jeff Korentur stated "Our intent is to create disruption in the pharmaceutical cannabinoid manufacturing space. We have demonstrated that these proprietary equipment and methods improve a wide range of API production metrics, and we look forward to partnering with customers that could benefit from these advantages."
Teewinot's Executive Vice President Dr. Richard Peet stated that "Teewinot's Irish subsidiary, FSL, owns a rapidly expanding patent portfolio covering processes for manufacture of cannabinoids, cannabinoid prodrugs and cannabinoid analogs. FSL's patent portfolio also covers novel cannabinoid prodrugs, cannabinoid analogs and treatment therapies. With federally licensed laboratories in Canada, an Irish subsidiary, and global headquarters in Tampa, Florida, Teewinot is well positioned to be a worldwide leader in the manufacture and delivery of cannabinoid-based therapies."
Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.
ACD/Labs Collaboration Provides NMR Data to Brazilian Biodiversity Natural Products DatabaseNews
ACD/Labs announces collaboration with researchers at Brazilian Biodiversity database in support of chemical and pharmaceutical R&D.READ MORE
A Promising Framework for Predicting Drug Resistance in CancerNews
The system works by predicting the co-occurrence of about 500 known tumour alterations, as well as their response to over 200 common cancer drugs.READ MORE